The stock’s next move may depend on whether this weaker share price history already reflects the main risks around Novo Nordisk or whether investors are still paying too much for its obesity drug potential. <\/p>\n
Compare Novo Nordisk’s reset valuation to other potential opportunities and review a hand picked list of 46 high quality undervalued stocks<\/a> that currently screen as priced below their assessed quality. <\/p>\n Is Novo Nordisk Still Cheap on Earnings? <\/p>\n P\/E is often a useful yardstick for a profitable pharma group like Novo Nordisk, since earnings are a key focus for shareholders. Novo Nordisk currently trades on a P\/E of 11.2x. This sits below the Pharmaceuticals industry average of 16.8x and also well below the peer group average of 49.6x, which points to a comparatively modest earnings multiple. <\/p>\n The fair P\/E ratio implied by the broader checks is 25.4x, which is more than double the current 11.2x level. That gap suggests the market is placing a cautious label on Novo Nordisk despite its established position in GLP-1 treatments and the cleaner narrative around Wegovy compared with some peers. Even with recent legal noise around competitors, the stock is still priced at a discount to what this tailored earnings framework would imply. <\/p>\n On this P\/E yardstick, Novo Nordisk stock appears undervalued relative to both its industry and its own fair multiple. <\/p>\n See what the numbers say about this price \u2014 find out in our valuation breakdown.<\/a> <\/p>\n The Novo Nordisk Narrative: What Would Justify Today’s Price? <\/p>\n Simply Wall St Narratives for Novo Nordisk pick up where this valuation puzzle leaves off and spell out what future growth, margins and earnings would need to look like for the stock to be worth materially more or less than today’s price. Each one turns Novo Nordisk’s implied fair value into a thesis about the business that can be revisited over time, rather than a single static number. <\/p>\n One of the top community narratives on Novo Nordisk: 51% undervalued <\/p>\n “Crucially, the market appears to assign little to no value to Novo’s development-stage pipeline beyond Wegovy, despite multiple GLP-1 and cardio-metabolic programs advancing…” <\/p>\n Read one of the top narratives<\/a> on Novo Nordisk<\/a> <\/p>\n Do you think there’s more to the story for Novo Nordisk? Head over to our Community to see what others are saying!<\/a> <\/p>\n The Bottom Line <\/p>\n Novo Nordisk screens as undervalued on earnings, with the current P\/E sitting well below both industry and tailored fair value markers. That gap only matters if the market is being overly cautious about how sustainable its GLP-1 and obesity franchise proves to be. For long term investors, the key question is whether legal and competitive risks in weight loss drugs justify this discount or whether it reflects an overly pessimistic read on Novo Nordisk’s earning power. The answer to that margin and durability debate is likely to decide whether today’s multiple is a genuine opportunity or a value trap. <\/p>\n This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. <\/p>\n Companies discussed in this article include NVO<\/a>. <\/p>\n Have feedback on this article? Concerned about the content? Get in touch<\/a> with us directly. Alternatively, email editorial-team@simplywallst.com<\/a> <\/p>\n","protected":false},"excerpt":{"rendered":"Novo Nordisk stock has given investors a difficult few years, with the share price down about 47.0% over…\n","protected":false},"author":2,"featured_media":154347,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[271],"tags":[272,948,277],"class_list":["post-154346","post","type-post","status-publish","format-standard","has-post-thumbnail","category-novo-nordisk","tag-novo-nordisk","tag-share-price","tag-weight-loss-drugs"],"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@dk\/117170307449303955","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts\/154346","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/comments?post=154346"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts\/154346\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/media\/154347"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/media?parent=154346"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/categories?post=154346"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/tags?post=154346"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}<\/a> NYSE:NVO P\/E Ratio as at Aug 2026 <\/p>\n